Metacrine (MTCR) Stock Price, News & Analysis

Company Overview

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.58 to $0.59
• 50-Day Range: $0.55 to $0.59
• 52-Week Range: $0.30 to $0.59
• Volume: 83,889 shs
• Average Volume: 225,834 shs
• Market Capitalization: $24.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MTCR Stock Analysis - Frequently Asked Questions

How were Metacrine's earnings last quarter?

Metacrine, Inc. (NASDAQ:MTCR) released its earnings results on Thursday, May, 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06.

When did Metacrine IPO?

Metacrine (MTCR) raised $84 million in an initial public offering (IPO) on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What other stocks do shareholders of Metacrine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR).

Company Calendar

• Last Earnings: 5/13/2021
• Today: 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MTCR
• CIK: 1634379
• Web: www.metacrine.com
• Phone: 858-369-7800
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-62,210,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.88%
• Return on Assets: -59.33%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 12.15
• Quick Ratio: 12.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 42,570,000
• Free Float: 36,695,000
• Market Cap: $24.75 million
• Optionable: Not Optionable
• Beta: -0.73